Empagliflozin in Acute Heart Failure

Chronic Kidney Diseases Clinical Trial

— DRIP-AHF-1  

Official title:

Empagliflozin for Patients With Acutely Decompensated Congestive Heart Failure, Diuretic Resistance, and Moderate to Advanced Chronic Kidney Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05305495
• Other study ID #: 2022-8411
• Status: Recruiting
• Phase: Phase 4
• Start date: December 22, 2022
• Est. completion date: July 2025

Study information

• Verified date: January 2023
• Source: McGill University Health Centre/Research Institute of the McGill University Health Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective is to study in a prospective, interventional, single arm, cohort study the potential synergistic diuretic effect of empagliflozin, in addition to furosemide, in hypervolemic patients admitted with acutely decompensated heart failure and diuretic resistance at the McGill University Health Centre (MUHC).

The investigators hypothesize that the sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin will enhance the diuretic effect of furosemide in patients with acutely decompensated heart failure, moderate to advanced chronic kidney disease, and underlying diuretic resistance, as identified by the three-hour urine output post diuretic administration on the first day of the study, compared with furosemide alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: July 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (all have to apply) :

• moderate to advanced CKD, defined as an eGFR <45 ml/min/1.73m2; The average creatinine values over the last 12 months will be used to calculate baseline eGFR.

• acutely decompensated heart failure, defined as dyspnea at rest or with minimal physical activity, associated with at least one clinical sign of congestion and at least one objective measure of heart failure (pulmonary-capillary wedge pressure >20 mm Hg or evidence of pulmonary congestion on chest radiography or brain natriuretic peptide (BNP) level =400 pg/ml or N-terminal pro-BNP level =1000 pg/ml);

• evidence of inadequate response to loop diuretics, defined as a urine output < 1000 ml/24h or a weight loss < 1kg /24h. For patients who have not received loop diuretics, a furosemide stress test can be conducted.

• stable hemodynamics, defined as systolic blood pressure >90 mmHg and/or mean arterial pressure >65 mmHg in the absence of intravenous norepinephrine or epinephrine in the last 24 hours.

Exclusion Criteria:

• new use of a non-loop diuretic other than an MRA

• history of type 1 diabetes mellitus

• euglycemic diabetic ketoacidosis

• liver disease defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening

• known hypersensitivity to SGLT-2 inhibitors

• use within the last 48 h of an SGLT-2 inhibitor or a combined SGLT-1 and SGLT-2 inhibitor

• maintenance dialysis or need for emergent renal replacement therapy

• gastrointestinal surgery or gastrointestinal disorder that could interfere with trial medication absorption

• recurrent severe genital or urinary tract infection

• pregnancy or breastfeeding

• any other clinical condition that would jeopardize patient safety while participating in this trial

• Patients with an acute rise in creatinine levels (acute cardiorenal syndrome) upon presentation will not be excluded.

Related Conditions & MeSH terms

• Acute Heart Failure
• Chronic Kidney Diseases
• Heart Failure
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Empagliflozin 25 MG
Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (=120 mg) and urine output will be monitored for three hours. Those with a urine output < 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.

Locations

Country	Name	City	State
Canada	Research Institute of the McGill University Health Center	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diuretic effect of empagliflozin in association with furosemide	Three-hour urine output post empagliflozin-furosemide administration, compared with furosemide alone	Day 1
Secondary	Fractional excretion of sodium in the urine	FeNa (%)	Day 1
Secondary	Total urine sodium output	Urine sodium per 24h	Day 1-5
Secondary	Changes in volume status	Net fluid balance	Day 1-5
Secondary	Incidence of AKI	Using the conventional KDIGO criteria	Day 1-5
Secondary	Electrolyte abnormalities - Sodium	Concentration of sodium	Day 1-5
Secondary	Electrolyte abnormalities - Potassium	Concentration of potassium	Day 1-5
Secondary	Electrolyte abnormalities - Magnesium	Concentration of magnesium	Day 1-5